The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly

Clinical Endocrinology

Volumn 62, Issue 6, 2005, Pages 742-747

  Gilbert, J A ^a   Miell, J P ^b   Chambers, S M ^a   McGregor, A M ^a   Aylwin, S J B ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 20444432736     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2005.02278.x     Document Type: Article

References (17)

1. Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J. & Ibbertson, H.K. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology (Oxford), 41, 95-102.
2. Bates, A.S., Van't Hoff, W., Jones, J.M. & Clayton, R.N. (1993) An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine, 86, 293-299.
3. Ayuk, J., Clayton, R.N., Holder, G., Sheppard, M.C., Stewart, P.M. & Bates, A.S. (2004a) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 1613-1617.
4. Holdaway, I.M., Rajasoorya, R.C. & Gamble, G.D. (2004) Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 667-674.
5. Swearingen, B., Barker, F.G., 2nd, Katznelson, L., Biller, B.M., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P.M. & Zervas, N.T. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419-3426.
6. Beauregard, C., Truong, U., Hardy, J. & Serri, O. (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clinical Endocrinology, 58, 86-91.
7. Newman, C.B., Melmed, S., George, A., Torigian, D., Duhaney, M., Snyder, P., Young, W., Klibanski, A., Molitch, M.E., Gagel, R., Sheeler, L., Cook, D., Malarkey, W., Jackson, I., Vance, M.L., Barkan, A., Frohman, L. & Kleinberg, D.L. (1998) Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3034-3040.
8. Colao, A., Ferone, D., Marzullo, P., Cappabianca, P., Cirillo, S., Boerlin, V., Lancranjan, I. & Lombardi, G. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and rumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism, 86, 2779-2786.
9. Cozzi, R., Attanasio, R., Montini, M., Pagani, G., Lasio, G., Lodrini, S., Barausse, M., Albizzi, M., Dallabonzana, D. & Pedroncelli, A.M. (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? Journal of Clinical Endocrinology and Metabolism, 88, 3090-3098.
10. Ayuk, J., Stewart, S.E., Stewart, P.M., Sheppard, M.C. & European Sandostatin LAR Group. (2004) Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clinical Endocrinology, 60, 375-381.
11. Freda, P.U. (2002) Somatostatin analogs in acromegaly. Review. Journal of Clinical Endocrinology and Metabolism, 87, 3013-3018.
12. Colao, A., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Di Sarno, A., Longobardi, S., Merola, B., Salvatore, M. & Lombardi, G. (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 81, 2356-2362.
13. Yang, I.M., Woo, J.T., Kim, S.W., Kim, J.W, Kim, YS. & Choi, Y.K. (1995) Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue. Clinical Endocrinology (Oxford), 42, 295-301.
14. Lamberts, S.W., Uitterlinden, P., Schuijff, P.C. & Klijn, J.G. (1988) Therapy of acromegaly with Sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clinical Endocrinology (Oxford), 29, 411-420.
15. Schmidt, K., Althoff, P.H., Harris, A., Hofmeister-Wagner, W., Schifferdecker, E. & Schoffling, K. (1990) Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests. Medizinische Klinik (Munich), 85, 700-706.
16. Melmed, S., Casanueva, F.F., Cavagnini, F., Chanson, P., Frohman, L., Grossman, A., Ho, K., Kleinberg, D., Lamberts, S., Laws, E., Lombardi, G., Vance, M.L, Werder, K.V., Wass, J. & Giustina, A. (2002) Guidelines for acromegaly management. Journal of Clinical Endocrinology and Metabolism, 87, 4054-4058.
17. Gilbert, J., Ketchen, M., Kane, P., Mason, T., Baister, E., Barr, S. & Harris, P.E. (2003) The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary, 6, 11-18.